Adalimumab in the management of refractory idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: a case report and literature review IRVAN – idiopathic retinal vasculitis, aneurysms and neuroretinitis – risks severe vision loss in refractory cases. In this case, marked improvement after anti-VEGF failure suggests adalimumab may be…

#MedCase - IRVAN risks severe vision loss in refractory cases.

In this case, marked improvement after anti-VEGF failure suggests #adalimumab may be an effective option that targets underlying inflammation.

👉 buff.ly/C1Kzo8j

#EyeSky

Beyond the Flare: A Case of Disseminated Tuberculosis and Thrombosis Masquerading as IBD Exacerbation A woman taking adalimumab for ileocolic Crohn’s disease presented with symptoms mimicking a flare. CT revealed extensive venous thrombosis, but respiratory symptoms developed and disseminated…

#MedCase - A woman taking #adalimumab for ileocolic #CrohnsDisease presented with symptoms mimicking a flare.

CT revealed extensive venous thrombosis, but respiratory symptoms developed and disseminated TB was diagnosed.

👉 buff.ly/eRNp0P9

#GastroSky #IDSky

It’s that day again 💉 those two weeks come round fast. 🤦🏻‍♂️ I’ve been injecting myself now for well over a year, and I still get scared of it. 😳
#ankylosingspondylitis
#Adalimumab

AbbVie turbocharges its US investment promise to $100bn AbbVie finally agrees a Most-Favoured Nation pricing deal with the US administration, with a $100 billion investment promise attached.

#AbbVie #bigpharma #mostfavourednationdrugpricing #MFN #MFNdrugpricing #pharmamanufacturing #MFNpricing #TrumpRx #DTCagreement #antiTNFantibody #Humira #adalimumab #biosimilars #glaucoma #Alphagan #brimonidine #Combigan #brimonidine #timolol #Synthroid #levothyroxine #hypothyroidism
zurl.co/mbw2t

Mabwell's Adalimumab Biosimilar Achieves Marketing Approval in Indonesia Mabwell's Adalimumab Biosimilar, known as 9MW0113, gains marketing authorization in Indonesia, enhancing global healthcare access and opportunities.

Mabwell's Adalimumab Biosimilar Achieves Marketing Approval in Indonesia #Indonesia #Jakarta #Mabwell #Adalimumab #JUNMAIKANG

Secondary ocular syphilis in an immunocompromised patient: a case report Ocular syphilis is an uncommon manifestation of its parent infection and may go undetected due to its nonspecific presentation. In this case, an atypical extraocular clinical presentation and a…

#MedCase - Ocular #syphilis is an uncommon manifestation of its parent infection and may go undetected.

In this case, an atypical extraocular clinical presentation and a history of #adalimumab therapy further complicated diagnosis.

👉 buff.ly/C7ORei3

#EyeSky #IDSky

Immunogenicity of Adalimumab in Bacterial Molecular Mimicry: In Silico Analysis Background: Adalimumab, a monoclonal antibody targeting TNFα, treats autoimmune diseases but induces anti-drug antibodies in 30–60% of patients, reducing its efficacy. Objective: This study investigates molecular mimicry as a mechanism behind this immunogenicity, where bacterial immunoglobulin domains structurally resemble adalimumab’s light chain, triggering immune responses. Methods: Using PSI-BLASTp and IBIVU Praline, there are 40 bacterial antigens homologous to adalimumab, with eight clinically relevant strains. Results: Structural analysis revealed 94% amino acid identity between the immunoglobulin domain of Escherichia coli strain B1 and adalimumab’s light chain, and 89.67% similarity with Corynebacterium pyruviciproducens. Root Mean Square Deviation values confirmed strong structural homology. Additionally, five cross-reactive B-cell epitopes were predicted, suggesting overlapping surfaces that may promote immune cross-reactivity and anti-drug antibody development. Conclusions: These findings emphasize the role of bacterial immunoglobulin domains in adalimumab immunogenicity and highlight further need for experimental validation and improved strategies to reduce immune responses in biological therapies.

Immunogenicity of Adalimumab in Bacterial Molecular Mimicry: In Silico Analysis #Adalimumab #Immunogenicity #AutoimmuneDiseases #BiologicTherapy #MolecularMimicry

- In a review of 23,458 patients exposed to adalimumab, the incidence rate of serious demyelinating disorders was ≤0.1 events per 100 person-years (Hamdan et al., 2024)
-The most frequently implicated TNF-α inhibitors in demyelinating events are #etanercept, #infliximab & #adalimumab

Cumulative hazard curve comparing hospitalization due to noncutaneous infections in Hidradenitis Suppurativa (HS) and Psoriasis cohorts. The HS curve(blue) is consistently higher than the Psoriasis curve(orange), with HR at 1.53; 95% CI, 1.34-1.86.

Among adults treated with #adalimumab, those with hidradenitis suppurativa have a higher risk of hospitalization due to noncutaneous infections, sepsis, and genitourinary infections. ja.ma/43F7Juc

New Data Show Upadacitinib's Superiority Over Adalimumab for RA Treatment Recent findings indicate that Upadacitinib outperforms Adalimumab in patients with insufficient response to TNF inhibitors, showing promise in RA treatment.

New Data Show Upadacitinib's Superiority Over Adalimumab for RA Treatment #United_States #North_Chicago #RA_Treatment #Upadacitinib #Adalimumab

FDA Expands Pediatric Use of YUFLYMA® and Unbranded Adalimumab-aaty for Chronic Conditions The FDA has approved YUFLYMA® and its unbranded counterpart for new pediatric uses, enhancing treatment options for chronic inflammatory diseases in kids.

FDA Expands Pediatric Use of YUFLYMA® and Unbranded Adalimumab-aaty for Chronic Conditions #United_States #Incheon #Celltrion #YUFLYMA® #Adalimumab

one huge video about adalimumab and my experiences on it
www.youtube.com/watch?v=O9eO...
#adalimumab #crohns #takayasus #immunosuppressant

Eyes on fire: a diagnostic and therapeutic dilemma Methotrexate resolved severe bilateral scleritis after adalimumab failed. Could conventional disease-modifying antirheumatic drugs outperform biologics in select ocular autoimmune cases with complex inflammatory...

#MedCase - Methotrexate resolved severe bilateral #scleritis after #adalimumab failed.

Could conventional disease-modifying antirheumatic drugs outperform biologics in select ocular autoimmune cases with complex inflammatory pathways?

👉 buff.ly/ryIfCox

#EyeMed #Methotrexate

Research Article

Efficacy of Tumor Necrosis Factor Inhibitors for Refractory Leg Ulcers in Cutaneous Polyarteritis Nodosa: A Case Series

📖 www.jrheum.org/cgi/content/...

#adalimumab #cutaneouspolyarteritisnodosa #vasculitis

...rauche auch nicht mehr...die Entzündung ist also alleine deshalb weniger bei Schüben. Kann die Wirkung von #adalimumab schwächer werden oder ganz verschwinden? Danke🙂

Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis This cohort study compares the risk of hospitalization from noncutaneous infections, infection profiles, and the length of stay of adult patients with hidradenitis suppurativa and psoriasis treated wi...

Pacientes con hidradenitis supurativa moderada a grave tratados con adalimumab tienen un riesgo elevado de infección y diferentes perfiles de infección comparados con los que tienen psoriasis #adalimumab #HS #psoriasis jamanetwork.com/journals/jam...

Retinal venous occlusion in drug-induced lupus Retinal venous occlusion in drug-induced lupus

Letter to editor
Retinal venous occlusion in drug-induced lupus
#Anti-TNF-Alpha #Retinal #Vein #Occlusion #Adalimumab #Drug-induced #Lupus #Erythematosus
www.em-consulte.com/article/1746...

#ICTSnews: Researchers from CIBER, CIPF & UPV/EHU develop non-invasive eye drops for retinitis pigmentosa with help from NANBIOSIS, showing promising results in preclinical models

🔗 more: www.nanbiosis.es/innovative-e...
#Nanomedicine #Ophthalmology #Adalimumab #CEBS #NanbiosisExpertise #CEBiomedS

I’ve uploaded one mega video of my experiences on #adalimumab for my #crohnsdisease and #takayasus !
Nothing much has changed so I thought making one large #IBD video on them might be useful to some!

#disabled #chronicillness #crohns #promosky #raredisease
youtu.be/O9eO3etfy8A?...

AI Predicts Life-Saving Drug for Rare Disease, Patient Enters Remission Researchers used an AI-driven approach to identify adalimumab as a potential life-saving treatment for idiopathic multicentric Castleman’s disease (iMCD), successfully reversing a terminal case. The b...

AI Predicts Life-Saving Drug for Rare Disease, Patient Enters Remission 🔬💊🤖 www.azoai.com/news/2025020... #AI #DrugRepurposing #RareDisease #MedicalBreakthrough #MachineLearning #PrecisionMedicine #HealthcareInnovation #LifesavingTech #CastlemanDisease #Adalimumab

Adalimumab Withdrawal in Uveitis Patients | RheumNow Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown ...

Adalimumab Withdrawal in Uveitis Patients
 
Only one-third of stable JIA-Uveitis could successfully discontinue adalimumab without flare of eye or joint disease

#Adalimumab #Uveitis

#TNF inhibitor
Anti-Rheumatic Rx
AS
#Spondyloarthritis

#Eye

rheumnow.com/news/adalimu....

#JIA #uveitis: Guidelines on 🛑 #adalimumab need to be updated. #ADJUST RCT just demonstrated high recurrence rate (68% among pts in the placebo group compared to 14% among adalimumab grp), regardless of time in remission on medication. @TheLancet www.thelancet.com/journals/lan...
#pedsrheum

Which is a medication #rheumatology at least work with regularly. It has been way better and hasnt been making me sick. But IBD pharm re still in charge of ordering my #adalimumab injections every 3 ish months. They used to be so on it, the delivery request was always pretty early.

Adalimumab-induced myoclonus: A potential adverse drug reaction? Adalimumab-induced myoclonus: A potential adverse drug reaction?

Adalimumab-induced myoclonus: A potential adverse drug reaction?
www.em-consulte.com/article/1712...
#Adalimumab #Myoclonus #ADRs #TNFAlphaInhibitors #Neurotoxicity #Pharmacovigilance

PET biodistribution study of subcutaneous and intravenous administration of adalimumab in an inflammatory bowel disease model Monoclonal antibodies targeting tumor necrosis factor-alpha (antiTNF-α) are used for patients with immuno-mediated illness as inflammatory bowel disea…

PET biodistribution study of subcutaneous and intravenous administration of #adalimumab in an #inflammatory #bowel disease model www.sciencedirect.com/science/arti... #hvhebron #mnucl #far

Yale School of Medicine Receives Grant From The Marcus Foundation to Treat Parkinson’s Disease The Marcus Foundation has awarded $13.2 million to Yale School of Medicine, to support a clinical trial that could mark a first step toward a preventive

medicine.yale.edu/news-article...
#adalimumab with FDG PET surrogate